Year-to-date money raised in public, private and other financings of biopharma companies.

Arkuda Therapeutics, a new company targeting progranulin and lysosomal biology to treat neurodegenerative diseases, has completed a $44 million series A financing.

"Global approval doesn't mean Australia approval. Government needs a new way of valuing the benefit of therapies that are a one-off cure differently than other drugs."

President Donald Trump has officially nominated Stephen Hahn to the position of FDA commissioner, a position held on an interim basis by Ned Sharpless since April. Hahn has held the position of CEO of the MD Anderson Cancer Center in Houston since May 2018.

Therapeutic area data reported by biopharma companies on phase I trials in October 2019.

Therapeutic area data reported by biopharma companies on phase II trials in October 2019.

Therapeutic area data reported by biopharma companies on phase III trials in October 2019.

The top 10 biopharma stock gainers and losers for the week of Nov. 4-8, 2019.

All of the biopharma stocks tracked by BioWorld, including their weekly and year-to-date percent changes and weekly trading volumes.

The oncology field pioneered adaptive trial designs through efforts such as I-SPY 2 (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2), Puma Biotechnology Inc.’s phase II study of the pan-HER tyrosine kinase inhibitor neratinib (Nerlynx) as neoadjuvant therapy in metastatic breast cancer, and the ongoing multidrug, biomarker-driven non-small-cell lung cancer trial known as Lung-MAP.